Communiqués Johnson & Johnson

Actions

JNJ

US4781601046

Produits pharmaceutiques

Marché Fermé - Nyse Autres places de cotation 22:00:02 10/07/2025			Après clôture 02:00:00
157,69 ^USD	+0,90 %		159,44	+1,11 %

10/07	JOHNSON & JOHNSON : Morgan Stanley confirme sa recommandation neutre	ZM
09/07	Les plus grandes acquisitions de l'industrie pharmaceutique et biotechnologique américaine de la dernière décennie	RE

Communiqués

IP Due Diligence: The Make-Or-Break Factor In Modern M&A	08/07	AQ
Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo	08/07	PR
Nuvve Holding Corp. Appoints Laura Huang and Brian Johnson to Board of Directors; New board members bring industry expertise in organizational transformation, mobility innovation, and strategic finance to support Nuvve's next phase of growth	04/07	AQ
Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations	04/07	AQ
Nuvve Holding Corp. Appoints Laura Huang and Brian Johnson to Board of Directors	04/07	AQ
Johnson & Johnson : submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations	03/07	PU
The Hackett Group(R) Announces Winners of the 2025 Hackett Innovation Awards	01/07	AQ
ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer	24/06	AQ
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)	23/06	PR
Johnson & Johnson Launches VOLT Wrist and Proximal Humerus Plating Systems in the U.S.	20/06	AQ
Johnson & Johnson : IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant	20/06	PU
Johnson & Johnson : Launches VOLT™ Wrist and Proximal Humerus Plating Systems in the U.S.	19/06	PU
Johnson & Johnsons Dual Targeting Car T Cell Therapy Shows Encouraging First Results In Large B Cell Lymphoma	16/06	AQ
Johnson & Johnson - Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease	16/06	AQ
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma	13/06	PR
Johnson & Johnson : Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison	12/06	PU
Johnson & Johnson - New data show TREMFYA is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis	12/06	AQ
Johnson & Johnson Launches the ETHICON 4000 Stapler for Elevated Surgical Experience and the Most Secure Staple Line Yet1	11/06	AQ
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors	10/06	BU
Wild Dark Shore by Charlotte McConaghy Claims Top Spot on Amazon's Best Books of 2025 So Far List; Amazon Books Editors unveil their selection of literary standouts from the first half of the year	06/06	AQ
Johnson & Johnson Launches KINCISE 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures	04/06	AQ
Johnson & Johnson : Launches KINCISE™ 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures	03/06	PU
Navigating Earn-Out Disputes: Key Considerations For Private Funds	30/05	AQ
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	28/05	BU
Legal And Financial Fallout Of The Bayer-Monsanto Merger: A Cautionary Tale In M&A Due Diligence	28/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

J&J s'attend à ce que les droits de douane coûtent 400 millions de dollars à l'entreprise

Le 15 avril 2025 à 17:30